Table 4.

Associations of fish oil supplement use with subsets of breast cancer defined by histology and stage, among female VITAL participants, (n=35,016)

	Fish Oil*
	Non-User		Current User
	Cases/Non-Cases	HR (95% CI)†,‡	Cases/Non-Cases	HR (95% CI)†,‡
Histology
Ductal Carcinoma (n=632)	579/30331	1.00 referent	29/2668	0.56 (0.38-0.83)
Lobular Carcinoma (n=172)	153/30331	1.00 referent	13/2668	1.08 (0.59-1.96)
p-diff				< 0.05
SEER Summary Stage
Local (n=626)	578/30331	1.00 referent	29/2668	0.57 (0.38-0.84)
Regional/Distant (n=251)	221/30331	1.00 referent	18/2668	0.97 (0.59-1.61)
p-diff				0.06
Hormone Receptor Status
ER+ (n=737)	669/30331	1.00 referent	29/2668	0.64 (0.46-0.91)
ER− (n=125)	118/30331	1.00 referent	1/2668	0.61 (0.27-1.40)
p-diff				0.49
PR+ (n=640)	584/30331	1.00 referent	22/2668	0.63 (0.43-0.92)
PR− (n=221)	202/30331	1.00 referent	8/2668	0.67 (0.36-1.23)
p-diff				0.96

^*Former users dropped from analysis

^†HR, Hazards Ratio; CI, Confidence Interval

^‡Adjusted for age, race, education, body mass index, height, fruit consumption, vegetable consumption, alcohol consumption, physical activity, age at menarche, age at menopause, age at first birth, history of hysterectomy, years of hormone therapy, family history of breast cancer, history of benign breast biopsy, mammography, low-dose aspirin use, regular aspirin use, ibuprofen use, naproxen use, use of multivitamins, memory loss, and coronary artery disease